News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 4.7.
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders
A comprehensive review published in Nature Reviews Clinical Oncology characterizes the spectrum of rare lymphoproliferative and lymphomatous disorders that can arise following chimeric antigen receptor (CAR) T cell therapy. The authors highlight recurrent pathological and molecular features of these post-treatment complications and identify factors that may drive clonal expansion and malignant tra…
FDA Staff Raises Concerns on Breast, Prostate Cancer Drug Applications
FDA staff have raised concerns about the benefit-risk profiles of two cancer drug applications targeting breast and prostate cancer, ahead of the first Oncologic Drugs Advisory Committee (ODAC) meeting since July of last year. The advisory committee is set to convene on Thursday to evaluate both applications, despite positive clinical trial results cited by the drug sponsors. The FDA's reservation…
FDA Opens Early Access to Novel Pancreatic Cancer Drug Generating Buzz
The FDA has issued a 'safe to proceed' letter to Revolution Medicines, authorizing an expanded access program (EAP) for the investigational pancreatic cancer drug daraxonrasib. Expanded access programs allow patients with serious or life-threatening conditions to receive experimental treatments outside of clinical trials when no comparable alternatives exist. Pancreatic cancer remains one of the d…
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
A study published in the Journal of Clinical Oncology presents a molecular-based ecosystem designed to improve personalized medicine approaches for patients with chronic myelomonocytic leukemia (CMML). CMML is a rare and heterogeneous myelodysplastic/myeloproliferative neoplasm with limited treatment options and variable clinical outcomes. The proposed framework integrates molecular profiling data…
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide
A study published in the Journal of Clinical Oncology examined patterns of radiographic progression in patients with advanced prostate cancer receiving enzalutamide, distinguishing between cases with and without a concurrent rise in prostate-specific antigen (PSA). The research provides important insights into how disease progression manifests differently in patients on androgen receptor-targeted …
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)
A phase II clinical trial published in the Journal of Clinical Oncology evaluated the combination of adebrelimab (an anti-PD-L1 checkpoint inhibitor) and bevacizumab with platinum-based chemotherapy in patients with triple-negative breast cancer (TNBC) who developed brain metastases. This patient population represents a particularly challenging clinical scenario with limited effective treatment op…
Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer
A study published in the Journal of Clinical Oncology examined the impact of Medicaid expansion on outcomes for patients with non-small cell lung cancer (NSCLC). The research assessed whether expanded insurance coverage led to earlier-stage diagnoses, more timely treatment initiation, greater adherence to guideline-concordant therapy, and improved survival. The findings contribute to the growing b…
Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status
A new study published in the Journal of Clinical Oncology examines how neighborhood socioeconomic status interacts with race to influence cancer outcomes among Black patients in the United States. The researchers found evidence of diminishing returns, meaning that improvements in neighborhood socioeconomic conditions yielded smaller survival and outcome benefits for Black patients compared to thei…
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study
A large international study from the SIOP WT 2001 trial has identified residual absolute volume of blastema as a predictor of clinical outcomes in patients with Wilms tumor, the most common kidney cancer in children. The findings, published in the Journal of Clinical Oncology, suggest that measuring blastema volume after preoperative chemotherapy can help stratify patients by risk and guide treatm…
[Articles] Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial
Secondary and exploratory analyses from the phase 3 ARANOTE trial demonstrate that darolutamide combined with androgen deprivation therapy (ADT) provides clinically meaningful delays in pain progression and time to deterioration of overall wellbeing in patients with metastatic hormone-sensitive prostate cancer (mHSPC). These patient-reported outcome data complement the previously established survi…